Cocrystal Pharma Receives UK MHRA Authorization To Initiate Its Phase 2a Influenza Human Challenge Trial With Oral PB2 Inhibitor CC-42344
Portfolio Pulse from Benzinga Newsdesk
Cocrystal Pharma, Inc. (NASDAQ:COCP) has received authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 2a human challenge trial for its oral PB2 inhibitor CC-42344, a potential treatment for pandemic and seasonal influenza A. The trial is expected to begin in Q4 2023. The company reported favorable safety and tolerability results from a Phase 1 trial in late 2022.
October 31, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cocrystal Pharma's stock may see positive movement as the company has received authorization to initiate a Phase 2a trial for its influenza treatment. This follows favorable Phase 1 trial results.
The news of the MHRA authorization for Cocrystal Pharma's Phase 2a trial is a significant positive development for the company. This could increase investor confidence in the company's pipeline, potentially leading to a rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100